



Paris 27-28 Janvier 2012




Niels Bækgaard  
Gentofte University Hospital  
Copenhagen

# CATHETER-DIRECTED THROMBOLYSIS OF ILIO-FEMORAL DVT 2012

The Copenhagen (**longest follow-up**) and Oslo experience (**RCT**)

# The options




**AC**

**CDT**



# Which patients could benefit from CDT?

Location	Distribution	Risk of PTS
● Crural DVT	30%	low+
● Crur/popl/fem DVT	25%	low++
● <b>Ilio-femoral DVT</b>	<b>25%</b>	<b>40%</b>
● Full-leg DVT	20%	50%++



Most papers on this level: Can we do something here?

R.Broholm, L. Panduro Jensen & N.Bækgaard, 2010.  
Catheter-directed thrombolysis of ilio-femoral venous thrombosis. A review.  
Int Angiol 2010

IVC


# Location


Eventually IVC  
involment

The ligament

The knee joint

Puncture site





# The Copenhagen experience

## ◎ Inclusion criteria for CDT of Ilio fem DVT

- distal popliteal vein as access vein (US)
- DVT duration  $\leq$  14 days
- first episode of DVT
- age  $<$  60 years
- informed consent from the patient

## ◎ Exclusion criteria

- active cancer
- surgery or delivery  $<$  7 days
- other contraindications to thrombolysis

## ◎ Diagnosis

- US and CT

Study: CT abdomen  
Serie: MPR, +IV 3/3  
Snit: 3 mm  
Pos.: 90  
HFS  
CONTRAST



CPH.UNIV.HOSP.HERLEV  
C: 60.0, W: 360.0


196 mAs  
120 kV  
Billednr.: 31  
Billede 31 af 65  
Total DLP: mGy\*cm  
**01-09-2009, 13:22:06**



CPH.UNIV.HOSP.HERLEV  
C: 60.0, W: 360.0



196 mAs  
120 kV  
Billednr.: 24  
Billede 24 af 65  
Total DLP: mGy\*cm  
**01-09-2009, 13:22:06**





# CDT of IF DVT


## ◎ The material

- period 1999-2010, 11½ years
- **150 limbs with IF DVT**
- median age 30 (15-57) years
- women/men 3:1
- left/right 4:1
- birth-control pills: 33%
- after delivery: 13%
- thrombophilia: 50%
  
- temporary cava filter: 6%
- caval atresia: 10%
- stenting (Wallstent): 60%
- median (1-6) days treatment 2,7 days


**11 % without risk factors**








PHILIPS



1. 8888



KAS GENTOFTE RUM 17


C: 511.5, W: 1023.0



SIN

trombolyse  
48 timer

05-10-2011, 11:19:58



KAS GENTOFTE RUM 17

C: 511.5, W: 1023.0



8 mm ballon

05-10-2011, 11:39:04




3


SIN

etter stent

PHILIPS



LOGIQ  
E9



# Haemostatic parameters

## ⦿ **Every 8 hours**

- Haemoglobin
- APTT
- Fibrinogen
- D-dimer
  
- Antitrombin
- Anti-Xa
- Platelets

**These patients do not stay in the ICU**

# Complications

## ⊙ **Minor bleeding**

- 27 %,
  - from the puncture site
  - haematuria

## ⊙ **Major bleeding**

- 2 %, from arterial puncture site, fasciotomy

## ⊙ **PE**



- 0 %

# Follow-up

- ⊙ **6 w – 3 m - 6m – 12m – yearly**
- ⊙ Clinical exam.:
  - Hawaii classification
- ⊙ Ultrasonography: same intervals
  - supine
    - the iliac vein/stent
    - the femoral vein
  - standing
    - the com.fem.vein
    - the femoral vein
    - the popliteal vein


} patency

} valve sufficiency




# Intention to Treat - Kaplan-Meier Plot

## Patency without reflux



# Intention to Treat - Kaplan-Meier Plot

## Patency without reflux



# PTS

Villalta score  
CEAP  
SF-36  
VEINES

- 109 patients
- 71 months mean follow-up
- 16 % PTS (½ mild)
- With significantly worse QoL scores
- Patients with competent veins had significantly higher QoL than patients with insufficiency



# The Oslo trial

N= 90 CDT + AC  
N= 99 AC

## Results after 6 months

### Patency IF vein

- CDT+AC: 66%
- AC: 45%

Disappointing results

### Reflux in CF vein

- CDT+AC: 60%
- AC: 66%

Reported on 50 patients

# The Oslo trial

## ⊙ Results after **2 years**

### • **PTS**

- **CDT + AC** 41 %
  - **AC** 55 %
- P=0,047

- **No needed to treat** 7

Disappointing results

- **Risk reduction** 14 %

Enden et al. Lancet 2012

# Copenhagen contra Oslo


- Age of the patient younger
- Duration of symptoms shorter
- Iliofemoral DVT all
- rt-PA  $\frac{1}{2}$  x more
- APTT higher
- Pulespray/cont. pulse
- Volumen per hour 4 x more
- D-dimer yes
- IPC yes
- Stent yes



# Better results!!!

Location	Distribution %	Risk of PTS
● Crural DVT	30%	low
● Crural-popl/fem DVT	25%	low++
● <b>Ilio-femoral DVT: CDT</b>	<b>25%</b>	<b>&lt; 20 %</b>
● Full-leg DVT: Surgery	20%	50 % ++

# The Attract trial



# Conclusion

- ◎ **Ilio-fem DVT** (“treat the easy ones”) in 2012, some evidence
  - CDT is safe
  - Easy to perform
  - No need for ICU
  - Caval atresia is not a contraindication
  - Takes a couple of days
  - Excellent medium and long-term results
  - PTS and QOL correlates to these results
  - The treatment duration can maybe be shorter with mechanical devices


We are waiting for:

**ATTRACT** Trial (USA)


**CAVA** Trial (NL)

*Thank you*

# The progress of thrombolysis



# Treatments per year/Denmark



**195 patients**